1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Bile Duct Cancer (Cholangiocarcinoma) - Drugs In Development, 2022, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers) and weight loss. Treatment includes chemotherapy and radiation therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Bile Duct Cancer (Cholangiocarcinoma) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 117, 95, 5, 11, 34, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages comprises 6, 2, 2, 1 and 3 molecules, respectively.
Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Bile Duct Cancer (Cholangiocarcinoma) - Overview
- Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development
- Bile Duct Cancer (Cholangiocarcinoma) - Drug Profiles
- Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects
- Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products
- Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects, 2022
- Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products, 2022
- Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbisko Therapeutics Co Ltd
- AbbVie Inc
- Ability Pharmaceuticals SL
- ABL Bio Inc
- ABM Therapeutics Inc
- ADC Therapeutics SA
- Advenchen Laboratories LLC
- Affimed GmbH
- Akeso Inc
- Alaunos Therapeutics Inc
- Alentis Therapeutics AG
- Alkermes Plc
- Alligator Bioscience AB
- Alphamab Oncology
- Alpine Immune Sciences Inc
- Ambrx Biopharma Inc
- Amgen Inc
- AngioGenex Inc
- Apexigen Inc
- Apollomics Inc
- Arbele Ltd
- Ascelia Pharma AB
- Aslan Pharmaceuticals Ltd
- AstraZeneca Plc
- Bavarian Nordic AS
- Bayer AG
- BeiGene Ltd
- Beijing Biostar Technologies Ltd
- Beijing Immunochina Pharmaceuticals Co Ltd
- Betta Pharmaceuticals Co Ltd
- BioMed Valley Discoveries Inc
- BioNTech SE
- Biosion Inc
- Biotheus Inc
- BJ Bioscience Inc
- Blueprint Medicines Corp
- Boehringer Ingelheim International GmbH
- Bold Therapeutics Inc
- Bristol-Myers Squibb Co
- CanBas Co Ltd
- Celldex Therapeutics Inc
- Celltrion Inc
- Celon Pharma SA
- Chong Kun Dang Pharmaceutical Corporation
- Corcept Therapeutics Inc
- Cornerstone Pharmaceuticals Inc
- CSPC Pharmaceutical Group Ltd
- CStone Pharmaceuticals Co Ltd
- Cyclacel Pharmaceuticals Inc
- CytoImmune Therapeutics Inc
- Daiichi Sankyo Co Ltd
- Delcath Systems Inc
- Delta-Fly Pharma Inc
- Duo Oncology Inc
- Eddingpharm Inc
- Eisai Co Ltd
- Elevation Oncology Inc
- Eli Lilly and Co
- Elucida Oncology Inc
- EpimAb Biotherapeutics Inc
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- Faron Pharmaceuticals Oy
- Fujifilm Holdings Corp
- Genenta Science SpA
- Genentech USA Inc
- GeneQuantum Healthcare Suzhou Co Ltd
- Genexine Inc
- GenFleet Therapeutics (Shanghai) Inc
- Genome & Co
- Genoscience Pharma
- Genosco Inc
- Gensun Biopharma Inc
- GI Innovation Co Ltd
- GO Therapeutics Inc
- GSK plc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- H3 Biomedicine Inc
- Hangzhou Bensheng Pharmaceutical Co Ltd
- Harbin Gloria Pharmaceuticals Co Ltd
- Harbour BioMed (Guangzhou) Co Ltd
- Heidelberg Pharma AG
- Heilongjiang ZBD Pharmaceutical Co Ltd
- Hutchison MediPharma Ltd
- Ikena Oncology Inc
- ImCare Biotech LLC
- Immix BioPharma Inc
- ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
- Immunitor Inc
- Incyte Corp
- Inmune Bio Inc
- InnoCare Pharma Ltd
- Innopharmax Inc
- Innovative Cellular Therapeutics Co Ltd
- Innovent Biologics Inc
- Intensity Therapeutics Inc
- Ipsen SA
- Jiangsu Hengrui Medicine Co Ltd
- Johnson & Johnson
- Kinnate Biopharma Inc
- Komipharm International Co Ltd
- KPC Pharmaceuticals Inc
- LaNova Medicines Ltd
- Leap Therapeutics Inc
- LegoChem Biosciences Inc
- Les Laboratoires Servier SAS
- Ligand Pharmaceuticals Inc
- LipoMedix Pharmaceutical Inc
- Luzitin SA
- MacroGenics Inc
- MedAnnex Ltd
- Medicenna Therapeutics Corp
- MediciNova Inc
- Medivir AB
- Merck & Co Inc
- Merck KGaA
- Merus NV
- Mina Therapeutics Ltd
- Mirati Therapeutics Inc
- Molecular Templates Inc
- Nanjing KAEDI Biotech Inc
- NanoCarrier Co Ltd
- Nerviano Medical Sciences SRL
- Netherlands Translational Research Center BV
- NGM Biopharmaceuticals Inc
- Nkarta Inc
- Northwest Biotherapeutics Inc
- Novartis AG
- NuCana Plc
- Nuvalent Inc
- Orgenesis Inc
- Otsuka Pharmaceutical Co Ltd
- Perseus Proteomics Inc
- Pfizer Inc
- Pharma Mar SA
- Pharmaxis Ltd
- Pieris Pharmaceuticals Inc
- Promontory Therapeutics Inc
- Provecs Medical GmbH
- Puma Biotechnology Inc
- Puretech Health Plc
- QED Therapeutics Inc
- Quadriga BioSciences Inc
- QureBio Ltd
- Recordati SpA
- RedHill Biopharma Ltd
- Redx Pharma Plc
- Relay Therapeutics Inc
- RemeGen Co Ltd
- Rhizen Pharmaceuticals SA
- Rigel Pharmaceuticals Inc
- Samyang Biopharmaceuticals Corp
- Sanofi
- Seagen Inc
- Senhwa Biosciences Inc
- Shandong Boan Biotechnology Co Ltd
- Shandong Buchang Pharmaceutical Co Ltd
- Shanghai Cell Therapy Group Co
- Shanghai Fosun Pharmaceutical (Group) Co Ltd
- Shanghai Haihe Biopharma Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Miracogen Inc
- Shanghai Novamab Biopharmaceuticals Co Ltd
- Shanghai Yingli Pharmaceutical Co Ltd
- Shouyao Holding Co Ltd
- Sihuan Pharmaceutical Holdings Group Ltd
- Sillajen Biotherapeutics
- Sirnaomics Ltd
- Sorrento Therapeutics Inc
- Starpharma Holdings Ltd
- SupremeCure Pharma Inc
- Suzhou Kebo Ruijun Biosciences Co Ltd
- Suzhou Zelgen Biopharmaceutical Co Ltd
- Symphogen A/S
- SynCore Biotechnology Co Ltd
- Syndax Pharmaceuticals Inc
- SyntheX Inc
- Taiho Oncology Inc
- Tango Therapeutics Inc
- TCR2 Therapeutics Inc
- Tempest Therapeutics Inc
- Toray Industries Inc
- Transcenta Holding Ltd
- TransThera Sciences (Nanjing) Inc
- TriSalus Life Sciences Inc
- Tyra Biosciences Inc
- VasGene Therapeutics Inc
- Verismo Therapeutics
- Virogin Biotech Ltd
- Vivesto AB
- WellMarker Bio Co Ltd
- Xencor Inc
- Zhangzhou Pien Tze Huang Pharmaceutical Co Ltd
- Zhejiang Borui Biopharmaceutical Co Ltd
- Zymeworks Inc
